Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
A First-in-human Phase I, Open-label, Multicentre, Dose Escalation Trial of BI 3819026 in Combination With Ezabenlimab in Patients With Unresectable Advanced or Metastatic Solid Cancers to Determine the Maximum Tolerated Dose (MTD) and Recommended Dose for Expansion (RDE)
This study is open to adults with advanced cancer. The purpose of this study is to find the highest dose of BI 3819026 that people with advanced cancer can tol…
Advanced Solid CancerMetastatic Solid Cancer
Estimated
~$10 – $7,500
Boehringer IngelheimNCT07607678
Phase 1
First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effe…
Advanced Solid Cancers
Estimated
~$10 – $7,500
BioNTech SENCT07186842